BUZZ-Vertex falls after Q4 profit, sales of gene therapy disappoint
Shares of drugmaker Vertex Pharmaceuticals VRTX.O fall 1.8% to $461 in morning trade
Co on Monday reported Q4 profit of $3.98/shr, missing analysts' est. of $4.03/shr - as per LSEG data
Q4 sales of co and partner CRISPR's CRSP.BN sickle-cell disease therapy, Casgevy, came in at $8 mln vs est. of $17.7 mln
Brokerage TD Cowen says sales of Casgevy could be hurt by adoption and manufacturing-related challenges; does not expect VRTX to post billion-dollar revenues for the therapy
VRTX forecast 2025 rev. of $11.75 bln to $12.0 bln, vs. est. of $11.84 bln
Co said it aims to launch five new treatments by 2028, which includes a next-generation cystic fibrosis drug and its recently approved non-opioid painkiller, Journavx
Stock has risen 11% in the last 12 months
Related Articles
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
Why Sanae Takaichi Winning Japan’s Diet Election Led to a Surge in Japanese Stock Indices？
TradingKey - Reports indicate that the ruling coalition led by Japanese Prime Minister Sanae Takaichi has secured a single-party majority in the parliamentary elections held on Sunday (February 8). Following the news, the yen weakened slightly, while the Nikkei Index surpassed 57,000 for the first t
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
